Thursday, October 19, 2006

More on Practice Guidelines

From the NYT story:

Three doctors at the National Institutes of Health have sharply criticized Eli Lilly for its efforts to promote the use of Xigris, an expensive treatment for patients with sepsis, an often deadly blood infection.

In an article published yesterday in The New England Journal of Medicine, the doctors wrote that Lilly — the nation’s sixth-largest drug maker — had manipulated treatment guidelines for sepsis patients to promote Xigris at the expense of older, cheaper and equally effective treatments.

Lilly says that it acted appropriately.

http://lawprofessors.typepad.com/tortsprof/2006/10/more_on_practic.html

Current Affairs, Experts & Science, Products Liability | Permalink

TrackBack URL for this entry:

http://www.typepad.com/services/trackback/6a00d8341bfae553ef00d834bda45553ef

Listed below are links to weblogs that reference More on Practice Guidelines:

Comments

Eli Lilly is a big drug company that puts profits over patients.

They covered up findings that their Zyprexa has a TEN times greater risk of causing type 2 diabetes

Daniel Haszard Eli Lilly zyprexa drug caused my diabetes http://www.zyprexa-victims.com

Posted by: Daniel Haszard | Oct 19, 2006 8:48:40 AM

Post a comment